Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Perspective Therapeutics (CATX) over the last 16 years, with Q2 2025 value amounting to $514000.0.

  • Perspective Therapeutics' Consolidated Net Income rose 20489.8% to $514000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $514000.0, marking a year-over-year increase of 10838.23%. This contributed to the annual value of -$949000.0 for FY2024, which is 8951.73% up from last year.
  • Perspective Therapeutics' Consolidated Net Income amounted to $514000.0 in Q2 2025, which was up 20489.8% from -$490000.0 recorded in Q2 2024.
  • Perspective Therapeutics' Consolidated Net Income's 5-year high stood at $1.3 million during Q2 2021, with a 5-year trough of -$5.2 million in Q4 2023.
  • Moreover, its 5-year median value for Consolidated Net Income was -$1.5 million (2023), whereas its average is -$1.5 million.
  • Per our database at Business Quant, Perspective Therapeutics' Consolidated Net Income soared by 21329.97% in 2021 and then crashed by 25438.34% in 2022.
  • Over the past 5 years, Perspective Therapeutics' Consolidated Net Income (Quarter) stood at -$1.6 million in 2021, then plummeted by 41.83% to -$2.3 million in 2022, then plummeted by 127.82% to -$5.2 million in 2023, then soared by 90.55% to -$490000.0 in 2024, then soared by 204.9% to $514000.0 in 2025.
  • Its Consolidated Net Income stands at $514000.0 for Q2 2025, versus -$490000.0 for Q2 2024 and -$459000.0 for Q1 2024.